Virobay, Inc.
http://www.virobayinc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Virobay, Inc.
BioNotebook: Two deals, two offerings, seven IPO updates
Bind couples with Merck; Idera connects with DMD patients; Mast, CTI BioPharma price offerings; and three companies prices IPOs, including INC Research, a CRO.
IPO TABLE: Biotech slides even after strong offerings
Biotechnology companies launched half of the initial public offerings completed by venture capital-backed companies in 2014, but the momentum behind the IPO boom is slowing.
Deals Shaping The Medical Industry, October 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August-September 2014.
IPO TABLE: Five biotech offerings coming soon after Affimed priced, eight others filed or set terms
The market for initial public offerings has been especially frothy for biotechnology companies during the past two years and the week of 15 to 19 September may illustrate perfectly the strange dichotomy at work in the IPO space.
Company Information
- Industry
- Biotechnology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice